MicroDose Therapeutx to Present at the 30th Annual Cowen Healthcare Conference on Tuesday, March 9th
MONMOUTH JUNCTION, N.J. USA – March 3, 2010 — MicroDose Therapeutx Inc. today announced that it has been invited to give a corporate presentation at Cowen & Company, LLC’s 30th Annual Healthcare Conference being held at the Boston Marriot Copley Place, Boston, MA from Monday March 8th through Thursday, March 11th, 2010.
Anand V. Gumaste, PhD, MicroDose’s President and Chief Executive Officer, will provide an overview of the company on Tuesday, March 9th at 10:00a.m. Eastern Standard Time.
About MicroDose Therapeutx
MicroDose Therapeutx Acquires Epix Pharmaceuticals Portfolio of Compounds for Treatment of Chronic Constipation and Irritable Bowel Syndrome with Constipation (IBS-C)
Acquisition expands MicroDose’s portfolio in its PolyCap® oral delivery platform
MONMOUTH JUNCTION, N.J. USA – December 1, 2009 — MicroDose Therapeutx Inc. today announced that it has acquired a portfolio of compounds for the potential treatment of chronic constipation, irritable bowel syndrome with constipation (IBS-C) and other diseases, from Epix Pharmaceuticals, Inc. (EPIX) (Lexington, MA). The lead compound in the portfolio, formerly known as EPX-16006, is a novel, highly selective, oral, small molecule, now called MDT-006. The compound is extremely potent, possibly allowing for once-a-day dosing, and has demonstrated efficacy and safety in preclinical studies. Because of MDT-006’s unique mechanism of action, it may also have application in non-gastrointestinal diseases. MicroDose intends to develop MDT-006 initially in an oral format using its PolyCap® delivery platform.
MicroDose Therapeutx Acquires ViroPharma Portfolio of Investigational Compounds for Treatment of Respiratory Syncytial Virus (RSV)
Acquisition expands MicroDose’s portfolio of proprietary products.
MONMOUTH JUNCTION, N.J. USA—November 9, 2009—MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA). The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637. This highly potent compound has demonstrated antiviral activity in preclinical studies in both prophylaxis and treatment, and was generally well tolerated in multiple adult volunteer Phase I studies. MicroDose plans to develop the newly acquired compound in dry powder format for inhalation via MicroDose’s novel dry powder inhaler (DPI).
FOR RELEASE
Monmouth Junction, NJ, USA—April 27, 2009— MicroDose Technologies, a leader in next generation drug delivery technologies, is now MicroDose Therapeutx (MDT). Founded in 1998 with the introduction of its revolutionary electronic dry powder inhaler among other technologies, privately held MicroDose Therapeutx focuses on the creation of products utilizing its proprietary drug delivery technologies.
The MDT name change reflects the expansion of its business, its capabilities and its products. The company plans to expand its portfolio from primarily third party products incorporating its technologies to one that includes internally developed specialty pharmaceutical products. Utilizing its game changing drug delivery technologies, MicroDose Therapeutx plans to create easy to use therapies with improved performance, safety and efficacy. In addition to its new name, MDT has launched a new web site, www.mdtx.com.
MONMOUTH JUNCTION, N.J., Aug. 5 /PRNewswire/ — MicroDose Technologies Inc. (MicroDose) today announced that the first clinical milestone in its collaboration with Merck & Co., Inc., through a Merck affiliate, has been achieved, triggering the first payment under the global license agreement for MicroDose’s dry powder inhaler (DPI) technology announced in March 2008.
MONMOUTH JUNCTION, N.J., March 3 /PRNewswire/ — MicroDose Technologies Inc. (MicroDose) today announced that it has entered into a global license agreement with Merck & Co., Inc., through an affiliate, for use of MicroDose’s proprietary dry powder inhaler (DPI) with Merck compounds. This agreement follows the successful completion of an exploratory study evaluating the MicroDose DPI technology.
Nottingham, UK, December 7, 2005 – Innovata plc (LSE: IOV.L) today announced the restructuring of the agreement between QDose, its joint venture with MicroDose Technologies Inc. (MicroDose), and Bristol-Myers Squibb Company (NYSE: BMY) relating to fast acting inhaled insulin. Bristol-Myers Squibb has decided to reallocate resources dedicated to QDose to other pipeline priorities and has transferred to QDose all rights to the product.
St. Paul, MN — (Businesswire) — July 19, 2004 — 3M and MicroDose Technologies, Inc. a privately held drug delivery company based in Monmouth Junction, New Jersey, announced today that the two companies have entered into an exclusive co-development and joint marketing agreement.
Monmouth Junction, NJ, USA, 4th December 2001— MicroDose Technologies Inc. ( MicroDose ), a leading drug delivery company, announced today the successful completion of a Phase I clinical study evaluating the pulmonary delivery of human insulin, being conducted with joint venture partner, Elan Corporation, plc ( Elan ).
Nottingham, UK – 30 November 1999 – Quadrant Healthcare plc (“Quadrant” or the “Company”), the UK drug delivery company, announced today that it has agreed to form a new joint venture company with MicroDose Technologies Inc (“MicroDose”), a US based drug delivery systems company, to develop and exploit the pulmonary delivery of peptides and proteins.
